白眉蛇毒血凝酶用于慢性泪囊炎患者鼻腔泪囊吻合术效果观察

Application of Hemocoagulase in Dacryocystorhinostomy for the Patients with Chronic Dacryocystitis

目的:观察白眉蛇毒血凝酶对慢性泪囊炎患者鼻腔泪囊吻合术的有效性和安全性。方法:116例(127眼)慢性泪囊炎患者随机分为试验组与对照组。对照组55例(60眼)行常规鼻腔泪囊吻合术;试验组61例(67眼)于常规鼻腔泪囊吻合术前30 min给予白眉蛇毒血凝酶2 u im。比较两组患者术中出血量,术后鼻腔渗血率、凝血功能和泪道通畅效果,记录药品不良反应。结果:试验组术中总失血量、术后1 d鼻渗血率等指标均明显低于对照组(P<0.05)。两组泪道通畅效果无明显差异;术前术后两组凝血功能指标无明显变化,治疗期间均未观察到明显不良反应。结论:白眉蛇毒血凝酶用于慢性泪囊炎患者鼻腔泪囊吻合术,可以显著降低术中出血量及术后鼻腔渗血率,安全有效。

Objective： To explore the clinical efficiency and safety of hemocoagulase used in dacryocystorhinostomy. Methods： Totally 116 cases （127 eyes） of patients with chronic dacryocystitis were randomly divided into the study group and the control group. The control group 55eases （60 eyes） only received daeryocystorhinostomy, while the study group 61cases （67 eyes） received 2 units of hemocoagulase intramuscularly before dacryocystorhinostomy. The intraoperative blood loss, nasal oozing rate of nasal cavity, coagula- tion function and patency of lacrimal passages after the operation were compared, and the adverse reactions were recorded as well Re- sults ： The intraoperative blood loss and nasal oozing rate of nasal cavity on the first day after the operation of the study group were lower than those in the control group （ P 〈 0.05 ）. For patency of lacrimal passages, there was no significant difference between the groups. After the operation, the coagulation function did not change in both groups. No obvious adverse reactions were observed in both groups. Conclusion： For the patients with chronic dacryocystitis, hemocoagulase can decrease the intraoperative blood loss and postoperative nasal oozing rate of nasal cavity for dacryocystorhinostomy.